Anthropic acquires one-person biotech Mithril Medicine and begins in-house drug development
Anthropic has acquired Mithril Medicine, a one-person startup pursuing treatments for rare muscular dystrophies, alongside unveiling six biopharma partnerships as part of an expanding drug discovery push.

Artificial intelligence lab Anthropic has acquired Mithril Medicine, a one-person biotechnology startup, and launched its own in-house drug discovery operations. Founded by Cody Tranbarger—known pseudonymously on X as "Professor Oak," according to Endpoints News—Mithril has been developing treatments for two rare forms of muscular dystrophy, including LAMA2-related muscular dystrophy. The acquisition was executed in July 2026, according to an update shared by MTS.[2][4][5][6]
Tranbarger operated Mithril by utilizing Anthropic's Claude AI model to coordinate contracts, logistics, and lab work across 11 external facilities. Anthropic reported that the AI-assisted workflow moved a candidate treatment from concept to promising preclinical results in mice in less than 18 months. Tranbarger is continuing the research internally at Anthropic, which stated that a candidate could advance to human clinical trials as soon as late 2028 if preclinical results hold up.[1][4][6]
Alongside its proprietary pipeline, Anthropic announced research collaborations with six life sciences organizations: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group. Anthropic highlighted early operational results from the partnerships, reporting that Generate Biomedicines used Claude to engineer a CAR-T component roughly 70% shorter than standard analogs, while Enveda processed 1,061 pages of manufacturing records in under three hours compared to the typical 25 hours.[1][3][6]
Key facts
- Anthropic acquired Mithril Medicine, a one-person startup developing therapies for two rare forms of muscular dystrophy.
- The acquisition closed in July 2026, according to an update shared by MTS.
- Mithril founder Cody Tranbarger ran the company using Claude to coordinate contracts, logistics, and experiments across 11 external labs.
- Endpoints News identified Tranbarger as the individual behind the pseudonymous X account 'Professor Oak.'
- Mithril progressed an experimental LAMA2 muscular dystrophy therapy from ideation to positive mouse trial results in less than 18 months, with human trials possible by late 2028.
- Anthropic unveiled drug discovery partnerships with BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group.
- Partner results included Generate Biomedicines designing a CAR-T component roughly 70% shorter than standard analogs and Enveda processing 1,061 manufacturing pages in under three hours.
Sources · 5 sources
- TA
Techstrong.ai@TechstrongaiPost on X ·
Anthropic has acquired Mithril Medicine, a one-person biotech startup whose founder used Claude to take an experimental LAMA2 muscular dystrophy therapy from ideation to positive preclinical mouse trials in under 18 months, with human trials possible by late 2028. Alongside the deal, Anthropic published early results from six partners, including Generate Biomedicines engineering a CAR-T component about 70% shorter than standard analogs and Enveda processing 1,061 pages of manufacturing records in under three hours instead of 25. Read the full article on what those collaborations produced and where Anthropic's life sciences push goes next: https://t.co/h4SWLReAtK #AgenticAI #Anthropic #DrugDiscovery #LifeSciences #Claude
Open source - QU
Quartz@qzPost on X ·
Anthropic is now running its own drug programs — and the results are wild Anthropic acquired a one-person biotech and is now pursuing in-house drug discovery, with early mouse trials showing real promise for a rare muscular dystrophy. #Anthropic #DrugDiscovery #MithrilMedicine https://t.co/RWSw1rlR8z
Open source - MT
MTS@MTSlivePost on X ·
SITUATION DETECTED: Anthropic has announced drug discovery partnerships with BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group, and has also begun drug discovery efforts of their own.
Open source - MT
MTS@MTSlivePost on X ·
SITUATION DETECTED: Anthropic acquired a one-person company in July 2026. Mithril Medicine - developing treatments for two rare forms of muscular dystrophy - owned and run by one person who used Claude to organize contracts, logistics, and experiments with 11 external labs.
Open source - EN
Endpoints News@endptsPost on X ·
Anthropic acquired Mithril Medicine, a one-person biotech run by the man behind the pseudonymous X account “Professor Oak.” https://t.co/G6SPTp9G46
Open source - WS
Wall St Engine@wallstenginePost on X ·
Anthropic has acquired Mithril Medicine, a one-person biotech startup, and is now running drug discovery programs of its own. Founder Cody Tranbarger used Claude to coordinate contracts, logistics and experiments with 11 external labs. Anthropic says that work took a potential treatment for a rare form of muscular dystrophy from an idea to promising results in mice in under 18 months. Mithril has been developing treatments for two rare forms of muscular dystrophy. Tranbarger is continuing the research at Anthropic, which says a drug could be ready to start human trials as early as late 2028 if the candidates continue to hold up. Anthropic also announced research partnerships with six organizations, including Bristol Myers Squibb, Generate Biomedicines and Enveda. The work spans drug design, manufacturing, regulatory documentation and clinical trial planning. Most of the research remains preclinical. The broader goal is to use Claude across the scientific and operational work required to move a potential medicine toward patients.
Open source

